Tarcocimab tedromer

Extended indication	Macular edema due to retinal vein occlusion (RVO)
Therapeutic value	Possible benefit in ease of use
Registration phase	Clinical trials

Product

Active substance	Tarcocimab tedromer
Domain	Neurological disorders
Reason of inclusion	New medicine (specialité)
Main indication	Eye disorders
Extended indication	Macular edema due to retinal vein occlusion (RVO)
Manufacturer	Kodiac
Route of administration	Intravitreal
Therapeutical formulation	Injection
Budgetting framework	Intermural (MSZ)
Additional remarks	Fabrikant: Kodiac Sciences Vascular endothelial growth factors inhibitors

Current treatment options	Bevacizumab en aflibercept worden op dit moment off-label gegeven.
Therapeutic value	Possible benefit in ease of use
Substantiation	Een voordeel is de toediening van eenmaal per 2 maanden ten opzichte van de huidige opties. Het betreft een VEGF-remmer en werkt op dezelfde aangrijpingspunten als de andere beschikbare geneesmiddelen.
Frequency of administration	1 times every 2 months
Dosage per administration	5mg
References	NCT04592419
Additional remarks	Intravitreal injection of KSI-301 (5 mg) at Day 1, Week 4, and once every 8 weeks through Week 20 followed by an individualized dosing regimen of Intravitreal injection of KSI-301 (5 mg) from Week 24 to Week 44.

References	Laouri M, Chen E, Looman M, Gallagher M. The burden of disease of retinal vein occlusion: review of the literature. Eye (Lond). 2011 Aug;25(8):981-8. doi: 10.1038/eye.2011.92. Epub 2011 May 6. PMID: 21546916; PMCID: PMC3178209.
Additional remarks	Bevolkingsstudies rapporteren een prevalentie van 0,5-2,0% van BVRO en 0,1-0,2% voor CRVO. Ongeveer 5-15% van de ogen met BRVO ontwikkelt macula-oedeem gedurende 1 jaar.

There is currently nothing known about the expected cost.

There is currently nothing known about the possible total cost.

There is currently nothing known about off label use.

There is currently nothing known about indication extensions.

There is currently no futher information available.